Trinity Biotech (TRIB) Fundamentals 2026 — Revenue Analysis | SniperIQ
Trinity Biotech (TRIB) is a IE-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
Trinity Biotech (TRIB) has a market capitalization of approximately
Trinity Biotech runs a net profit margin of -85.3%, a gross margin of 35.4%, and an operating margin of -25.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Trinity Biotech reported revenue of $44M for fiscal year 2025, with net income of -
Trinity Biotech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Trinity Biotech carries a debt-to-equity ratio of -1.92x and a current ratio of 0.25x, with a market beta of 1.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Trinity Biotech (TRIB) the key facts are: market cap
Get Trinity Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.